Real talk.

This retrospective look at a Canadian cancer registry reveals median survival after HER2-targeted therapies for metastatic breast cancer is sadly significantly worse than that achieved on trial with both pertuzumab (41 months in real world versus 57 on trial) and TDM-1 (15 months in real world versus 30 on trial). | Ethier, JAMA Oncol 2021